Some dermatologists recommend never using them in the same routine
Absolute Contraindications BPC-157 is not recommended for patients with: Active cancer (any type) theoretical concern regarding angiogenesis promotion Pregnancy or breastfeeding insufficient safety data Known hypersensitivity to any component of the formulation Relative Contraindications (Require Individualized Assessment) History of cancer after completion of treatment, a waiting period and oncology clearance may be appropriate Autoimmune disease especially if active or requiring immunosuppressive therapy Anticoagulant use injection site bleeding risk, though minimal with proper technique Severe renal or hepatic impairment dosing adjustments may be needed Monitoring and Follow-Up Patients on BPC-157 protocols are monitored through: Baseline and follow-up labs including inflammatory markers (CRP, ESR), complete blood count, and metabolic panel Clinical assessments pain scores, range of motion, functional outcomes at 2-week, 4-week, and 8-week intervals Imaging when indicated repeat ultrasound or MRI for musculoskeletal conditions to document structural healing The Patient Journey: What to Expect For patients considering peptide therapy, understanding the timeline of response helps set realistic expectations
Note important products of the transmethylation pathway and transsulfuration pathway shown
Its antioxidant-rich formula supports skin health while delivering visible results over time
The peptide has also demonstrated anti-aggression effects, reducing physical attacks by 5-fold in stimulated environments at very low doses
Therefore, although the researchers were able to demonstrate that intranasal glutathione supplementation could have a positive impact on patient symptoms, they failed to demonstrate these effects were distinct from a placebo effect
